155 related articles for article (PubMed ID: 28192404)
21. 9 Structure and function of isoprenylcysteine carboxylmethyltransferase (Icmt): A key enzyme in CaaX processing.
Anderson JL; Hrycyna CA
Enzymes; 2006; 24():245-72. PubMed ID: 26718043
[TBL] [Abstract][Full Text] [Related]
22. Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin β3 recycling, cell migration and cancer metastasis.
Do MT; Chai TF; Casey PJ; Wang M
Oncogene; 2017 Oct; 36(41):5757-5767. PubMed ID: 28604748
[TBL] [Abstract][Full Text] [Related]
23. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
24. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate.
Winter-Vann AM; Kamen BA; Bergo MO; Young SG; Melnyk S; James SJ; Casey PJ
Proc Natl Acad Sci U S A; 2003 May; 100(11):6529-34. PubMed ID: 12750467
[TBL] [Abstract][Full Text] [Related]
25. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells.
Bergo MO; Leung GK; Ambroziak P; Otto JC; Casey PJ; Young SG
J Biol Chem; 2000 Jun; 275(23):17605-10. PubMed ID: 10747846
[TBL] [Abstract][Full Text] [Related]
26. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.
Wahlstrom AM; Cutts BA; Liu M; Lindskog A; Karlsson C; Sjogren AK; Andersson KM; Young SG; Bergo MO
Blood; 2008 Aug; 112(4):1357-65. PubMed ID: 18502828
[TBL] [Abstract][Full Text] [Related]
27. Deficiency of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) Leads to Progressive Loss of Photoreceptor Function.
Christiansen JR; Pendse ND; Kolandaivelu S; Bergo MO; Young SG; Ramamurthy V
J Neurosci; 2016 May; 36(18):5107-14. PubMed ID: 27147662
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the kinetic mechanism of recombinant human isoprenylcysteine carboxylmethyltransferase (Icmt).
Baron RA; Casey PJ
BMC Biochem; 2004 Dec; 5():19. PubMed ID: 15625008
[TBL] [Abstract][Full Text] [Related]
29. Adenosine dialdehyde suppresses MMP-9-mediated invasion of cancer cells by blocking the Ras/Raf-1/ERK/AP-1 signaling pathway.
Kim JH; Kim JH; Kim SC; Yi YS; Yang WS; Yang Y; Kim HG; Lee JY; Kim KH; Yoo BC; Hong S; Cho JY
Biochem Pharmacol; 2013 Nov; 86(9):1285-300. PubMed ID: 23994169
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth.
Wang M; Hossain MS; Tan W; Coolman B; Zhou J; Liu S; Casey PJ
Oncogene; 2010 Sep; 29(35):4959-70. PubMed ID: 20622895
[TBL] [Abstract][Full Text] [Related]
31. The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer.
Siprashvili Z; Webster DE; Johnston D; Shenoy RM; Ungewickell AJ; Bhaduri A; Flockhart R; Zarnegar BJ; Che Y; Meschi F; Puglisi JD; Khavari PA
Nat Genet; 2016 Jan; 48(1):53-8. PubMed ID: 26595770
[TBL] [Abstract][Full Text] [Related]
32. The role of wild type RAS isoforms in cancer.
Zhou B; Der CJ; Cox AD
Semin Cell Dev Biol; 2016 Oct; 58():60-9. PubMed ID: 27422332
[TBL] [Abstract][Full Text] [Related]
33. The RAS-Effector Interaction as a Drug Target.
Keeton AB; Salter EA; Piazza GA
Cancer Res; 2017 Jan; 77(2):221-226. PubMed ID: 28062402
[TBL] [Abstract][Full Text] [Related]
34. Isoprenylcysteine carboxy methyltransferase (ICMT) is associated with tumor aggressiveness and its expression is controlled by the p53 tumor suppressor.
Borini Etichetti C; Di Benedetto C; Rossi C; Baglioni MV; Bicciato S; Del Sal G; Menacho-Marquez M; Girardini J
J Biol Chem; 2019 Mar; 294(13):5060-5073. PubMed ID: 30655292
[TBL] [Abstract][Full Text] [Related]
35. Rationale for RAS mutation-tailored therapies.
Montalvo SK; Li L; Westover KD
Future Oncol; 2017 Feb; 13(3):263-271. PubMed ID: 27728979
[TBL] [Abstract][Full Text] [Related]
36. The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.
Kovalski JR; Bhaduri A; Zehnder AM; Neela PH; Che Y; Wozniak GG; Khavari PA
Mol Cell; 2019 Feb; 73(4):830-844.e12. PubMed ID: 30639242
[TBL] [Abstract][Full Text] [Related]
37. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
38. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
39. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis.
Jeng HH; Taylor LJ; Bar-Sagi D
Nat Commun; 2012; 3():1168. PubMed ID: 23132018
[TBL] [Abstract][Full Text] [Related]
40. ISGylation governs the oncogenic function of Ki-Ras in breast cancer.
Burks J; Reed RE; Desai SD
Oncogene; 2014 Feb; 33(6):794-803. PubMed ID: 23318454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
